Luye Pharma Group Stock Fundamentals
| LYPHF Stock | USD 0.34 0.00 0.00% |
Luye Pharma Group fundamentals help investors to digest information that contributes to Luye Pharma's financial success or failures. It also enables traders to predict the movement of Luye Pink Sheet. The fundamental analysis module provides a way to measure Luye Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Luye Pharma pink sheet.
Luye |
Luye Pharma Group Company Return On Asset Analysis
Luye Pharma's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Luye Pharma Return On Asset | 0.0081 |
Most of Luye Pharma's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Luye Pharma Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Luye Pharma Group has a Return On Asset of 0.0081. This is 100.09% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The return on asset for all United States stocks is 105.79% lower than that of the firm.
Luye Pharma Group Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Luye Pharma's current stock value. Our valuation model uses many indicators to compare Luye Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Luye Pharma competition to find correlations between indicators driving Luye Pharma's intrinsic value. More Info.Luye Pharma Group is rated third overall in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Luye Pharma's earnings, one of the primary drivers of an investment's value.Luye Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Luye Pharma's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Luye Pharma could also be used in its relative valuation, which is a method of valuing Luye Pharma by comparing valuation metrics of similar companies.Luye Pharma is currently under evaluation in return on asset category among its peers.
Luye Fundamentals
| Return On Equity | -0.0261 | |||
| Return On Asset | 0.0081 | |||
| Profit Margin | (0.04) % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 2.08 B | |||
| Shares Outstanding | 3.55 B | |||
| Shares Owned By Insiders | 35.41 % | |||
| Shares Owned By Institutions | 24.08 % | |||
| Price To Book | 2.17 X | |||
| Price To Sales | 0.47 X | |||
| Revenue | 5.2 B | |||
| Gross Profit | 3.4 B | |||
| EBITDA | 324.9 M | |||
| Net Income | (134.39 M) | |||
| Total Debt | 4.21 B | |||
| Debt To Equity | 1.15 % | |||
| Current Ratio | 1.46 X | |||
| Book Value Per Share | 2.54 X | |||
| Cash Flow From Operations | 182.37 M | |||
| Earnings Per Share | 0.03 X | |||
| Number Of Employees | 4.8 K | |||
| Beta | 0.93 | |||
| Market Capitalization | 2.66 B | |||
| Total Asset | 22.58 B | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 22.58 B |
About Luye Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Luye Pharma Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Luye Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Luye Pharma Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Luye Pharma Group Ltd. develops, produces, markets, and sells pharmaceutical products worldwide. The company was founded in 1994 and is headquartered in Yantai, the Peoples Republic of China. Luye Pharma is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Other Information on Investing in Luye Pink Sheet
Luye Pharma financial ratios help investors to determine whether Luye Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Luye with respect to the benefits of owning Luye Pharma security.